HOME >> MEDICINE >> NEWS
New synthetic antithrombotic drug could reduce dvt risk after hip surgery

Two studies in this weeks issue of THE LANCET highlight how a new class of synthetic antithrombotic drug could be more effective than conventional therapy in reducing the risk of potentially fatal blood clots associated with hip-replacement surgery.

Between 16 and 30% of patients who undergo Hip-replacement surgery have a risk of developing deep-vein thrombosis (DVT)-even when anti-clotting agents such as heparin and warfarin are used. DVT from hip surgery can occasionally result in death due to pulmonary embolism (in around 0.1-0.4% of cases). Michael Rud Lassen from University Hospital Copenhagen, Hillerd, Denmark, and colleagues assessed the ability of fondaparinux, the first of a new class of synthetic antithrombotic agents, to further reduce DVT risk.

Around 2300 patients from 16 European countries who were undergoing elective hip-replacement surgery were randomly assigned to once daily injections of either 2.5 mg fondaparinux, starting postoperatively, or 40 mg of the anti-clotting agent enoxaparin, starting preoperatively. Analysis was based on the outcomes of 79% of the patients who took part in the study. By the eleventh day after surgery, venous thromboembolisms were recorded in 4% of patients assigned fondaparinux and in 9% assigned enoxaparin. The two groups did not differ in frequency of death or clinically relevant bleeding.

A second study in this weeks issue of THE LANCET by the same team of investigators (led by Alexander Turpie from Hamilton Health Sciences, Canada), compared the effects of fondaparinux with enoxaparin when either drug was given postoperatively to patients after hip-replacement surgery. 2275 patients were recruited from the USA, Canada, and Australia; there was a 26% reduction in venous thromboembolism among patients given fondaparinux which was clinically (but not statistically) significant

In an accompanying Commentary (p 1710), Henri Bounameaux from University Hospitals of Geneva, Switzerla
'"/>

Contact: Richard Lane
richard.lane@lancet.com
44-20-7424-4949
Lancet
16-May-2002


Page: 1 2

Related medicine news :

1. Brookhaven Lab and BioSET develop a synthetic peptide that enhances the effect of BMP-2
2. Chemist works to prevent undesirable side effects in synthetic drugs
3. Chemists create synthetic cytochromes
4. Study shows synthetic pheromone in womens perfume increases intimate contact with men
5. Engineers use computer simulation to design synthetic blood vessels
6. Charcoal and forest management could reduce greenhouse gas levels & save lives in Africa
7. Novel therapy tested in mice could chase away cat allergies
8. Costs of antidepressants could have funded effective alternatives
9. Emergency clopidogrel could save thousands of lives46,000-patient heart attack trial results
10. Blood pressure treatment could cut risk of strokes and heart attacks
11. Proteins found in urine of pregnant women could help diagnose preeclampsia

Post Your Comments:
(Date:5/21/2013)... 2013 Parker Waichman LLP, a national ... injured by defective medical devices, is addressing new research ... on May 15, 2013. The study found that magnetic ... that occur in patients with metal-on-metal hip implants even ... ) , “We’ve known for quite ...
(Date:5/21/2013)... 2013 Artisan Business Group is ... Dealmakers Conference in Long Beach, California on May ... exploring alternative finance through EB-5 immigrant investors program. ... and economic information, and updates to project developers, ... the EB-5 industry. , "Our goal is ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 Arizona ... inventors who want to develop their ideas into ... program. , The university is recruiting participants ... new “formation space” that provides early-stage entrepreneurs with ... AREA48 is open to anyone, ASU is particularly ...
(Date:5/21/2013)... The In View series , a ... channels across the country, announces it has posted a ... producers of the series proudly bring audiences across the ... manufacturing industry, health-related companies, medical facilities and more. The ... in all parts of the United States, Canada and ...
(Date:5/21/2013)... 21, 2013 Global Proving Ground (GPG), ... the largest online retailer of health and fitness supplements, ... sports show, Warrior Island. “We cast the show ... & Twitter, with our unique social networking platform,” states ... elite fighters on an island in the Pacific Ocean, ...
Breaking Medicine News(10 mins):Health News:Parker Waichman LLP Comments on New Study Showing that MRI is Useful for Predicting Failure of Metal-on-Metal Hip Implants 2Health News:Parker Waichman LLP Comments on New Study Showing that MRI is Useful for Predicting Failure of Metal-on-Metal Hip Implants 3Health News:Artisan Business Group to Host EB-5 Investment Conference in Long Beach, California 2Health News:ASU Launches Summer Program for Aspiring Entrepreneurs, Innovators and Inventors 2Health News:ASU Launches Summer Program for Aspiring Entrepreneurs, Innovators and Inventors 3Health News:ASU Launches Summer Program for Aspiring Entrepreneurs, Innovators and Inventors 4Health News:In View hosted by Larry King Announces New Videos on its YouTube Channel 2Health News:Bodybuilding.com Partners with Global Proving Ground’s New Reality Show Warrior Island 2Health News:Bodybuilding.com Partners with Global Proving Ground’s New Reality Show Warrior Island 3
(Date:5/21/2013)... N.J. , May 21, 2013 /PRNewswire-iReach/ -- The ... in NJ has attracted the greatest number of ... its President, Mark Alexay .  ... plans to attend this year.  The show,s still 4 ... different companies.  This is a big surprise and ...
(Date:5/21/2013)... BURLINGTON, Mass. , May 21, 2013 ... leading research and advisory firms for pharmaceutical ... of an emerging agent on key efficacy ... disease progression, has the most influence over ... for advanced/metastatic hormone-receptor (HR-) positive, HER2-negative breast ...
(Date:5/21/2013)... 2013  IsoRay, Inc. (AMEX: ISR ), ... into an exclusive international distribution agreement with IASIS Medical ... Greece . IsoRay is a medical ... radioisotope applications for brain cancer, lung cancer, head and ... IASIS Medical is ideally suited to support ...
Breaking Medicine Technology:Emerging Pharma at ChemOutsourcing 2013 in Record Numbers for Upcoming September Show 2Thought-Leader Opinion and Clinical Data Indicate that Emerging Agents from Two Drug Classes Have Efficacy Advantages Over Currently Used Therapies for HR-Positive, HER2-Negative Breast Cancer 2IsoRay Announces A New International Distributor For Greece 2IsoRay Announces A New International Distributor For Greece 3
Cached News: